GlobeNewswire

Aducanumab is good; next generation Alzheimer’s disease therapies will be better

Share

New data for aducanumab strengthens potential for Alzheimer’s therapy in near term, fuels next-generation therapies with more selective binding for toxic species of amyloid beta

TORONTO and CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, commends Biogen for its trailblazing efforts to advance aducanumab. Data released today at CTAD (Clinical Trials on Alzheimer’s Disease conference) strengthen aducanumab’s potential to become the first disease-modifying therapy for Alzheimer’s disease. The data clearly underscore the need for next-generation drug candidates that offer more precise binding to the misfolded beta amyloid oligomer (AßO), the toxic species of the amyloid beta protein and root cause of Alzheimer’s disease.

“Today’s presentation reflects yet another landmark step toward the approval of a disease-modifying therapy for Alzheimer’s disease, which, we must remember, is currently the only top-ten cause of death without treatment,” said ProMIS Neurosciences Chief Medical Officer James Kupiec, MD. “The aducanumab data is indeed good news, but the compound has limitations. History frequently shows that first-generation therapies for the most challenging diseases often have major efficacy or safety limitations.  In heart disease, cancer and HIV, first-generation efforts often paved the way for better, safer medicines, and the same will be true for Alzheimer’s disease by more precisely targeting only the toxic species of amyloid beta and thereby avoiding the dose-limiting side effects associated with unwanted off-target binding. We will get there.  Biomarkers will help us get there faster, but aducanumab is a tremendous first step.”

New data for aducanumab affirm a statistically significant reduction in cognitive and functional decline for participants in the EMERGE trial. As clinical benefit depends on the amount of antibody that can reach the pathogenic species of amyloid beta, data continue to show that aducanumab demonstrates limited selectivity for AßOs: off-target binding to amyloid plaque was associated with adverse and dose-limiting ARIA-E (brain swelling) in 35% of trial participants despite attempts to minimize it by titrating drug dosing.

PMN310 is a next generation drug candidate that offers more precise selectivity for AßOs, which is expected to provide greater clinical benefit and safety based upon current preclinical data. Created using a novel drug discovery and development platform that can uniquely and precisely target the toxic forms of otherwise normal proteins, PMN310 demonstrates a high degree of binding to toxic oligomers without binding to non-toxic forms of amyloid beta. Data also demonstrate PMN310’s greater therapeutic potency versus other Aß-directed antibodies. For more information about PMN310, please visit www.promisneurosciences.com.

To learn more about the search for therapies for Alzheimer’s, Parkinson’s and other neurodegenerative diseases, listen to Saving Minds, at iTunes or Spotify.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

For media inquiries, please contact:
Shanti Skiffington
shanti.skiffington@gmail.com
Tel. 617 921-0808

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Verisk Reports Second-Quarter 2020 Financial Results4.8.2020 22:00:10 CESTPress release

•Consolidated revenues were $679 million, up 4.0%, and up 1.1% on an organic constant currency (OCC) basis for the second quarter of 2020. •Net income was $179 million, up 19.0% for the second quarter of 2020. Adjusted EBITDA, a non-GAAP measure, was $348 million, up 14.5%, and up 12.4% on an OCC basis. •Diluted GAAP earnings per share (diluted EPS) were $1.08 for the second quarter of 2020. Diluted adjusted earnings per share (diluted adjusted EPS), a non-GAAP measure, were $1.29. •Net cash provided by operating activities was $250 million, up 24.6% for the second quarter of 2020. Free cash flow, a non-GAAP measure, was $193 million, up 25.7%. •The company paid a cash dividend of 27 cents per share on June 30, 2020. The company's Board of Directors approved a cash dividend of 27 cents per share payable on September 30, 2020. •The company repurchased $75 million of its shares during the second quarter of 2020. •The company currently has $995 million of undrawn capacity on its revolver

EVS Broadcast Equipment: EVS publish a transparency notification4.8.2020 17:45:00 CESTPress release

Publication on August 4, 2020, after market closing Regulated information – Transparency notification EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS publish a transparency notification (Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings) On July 31, 2020, through the execution of its Share Buy back program announced on May 6, 2020, EVS Broadcast Equipment crossed up the threshold of 5%. Taking into account the additional shares bought back on August 3rd, EVS now holds, by virtue of acquisitions of shares, 5.02% of the voting rights of the company as of August 3rd. EVS broadcast Equipment has then issued a Transparency notification dated August 3rd, 2020, which contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rights Notification by: a person that notifies alone Persons subject to the notification requirement: EVS Broadcast Equipme

USD TENDER OPERATION ANNOUNCEMENT4.8.2020 16:20:00 CESTPress release

USD TENDER OPERATION ANNOUNCEMENT AUG 6, 2020 Transaction type: Reverse TransactionOperation type:Liquidity providingTender date:AUG-06-2020Time for submission of bids14.00-14.30 (CEST)Start date:AUG-10-2020Maturity date:NOV-02-2020Duration:84 daysOffered volume:USD 10.0 bln Min bid amount: USD 100 mlnMaximum bid amount: USD 4.0 blnMax number of bids:10Lowest interest supplement:0.25 percentage pointsMin bid rate:t.b.a.Allocation time:15.00 (CEST) on Tender date Approved counterparties are invited to submit bids to the Riksbank, tel +46 8 6966970 by 14.30 (CEST) on August 6, 2020. Confirmation of bids to e-mail: https://www.globenewswire.com/Tracker?data=9m1W_QdYv8-B3GJ6GXxvzn1Zuavk3Ej_p11v6Jp1r2LLxdgXieni84t6RH6PkJOv06P94eHVLH971JznSWubyA== eol@riksbank.se